Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Commercial preparations include an expanded sales force, while quarterly administrative expenses rose to $37.419 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics (MLYS) reported third-quarter financial results while preparing for a potential commercial launch of its hypertension drug lorundrostat. The FDA review has a December 22, 2026 target decision date; approval remains pending. An expanded medical affairs team and sales force are in place.
In Launch-HTN, 46% of participants receiving 50 mg reached office systolic blood pressure below 130 mmHg at Week 12. Explore-OSA showed lower morning blood pressure but no measurable change in sleep apnea frequency. Third-quarter net loss widened to $57.328 million from $36.932 million a year earlier as administrative expenses rose, while research expenses fell. Cash, cash equivalents and investments totaled $624.672 million at September 30, versus $656.635 million at December 31, 2025. Mineralys expects its funds to support planned operations, including launch, into 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointLaunch-HTN: 46% receiving lorundrostat 50 mg reached systolic blood pressure below 130 mmHg at Week 12.
- Moderate pointLaunch-HTN: more than two-thirds receiving lorundrostat 50 mg achieved systolic blood pressure reductions of ≥10 mmHg at Week 12.
- Moderate pointLaunch-HTN showed 52% lower albuminuria, or urine albumin levels, versus placebo.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Mineralys expects current funds to support planned operations, including lorundrostat launch, into 2028.
- Minor pointLaunch-HTN showed similar blood pressure reductions with and without chronic kidney disease, consistent across Stages 1–3.
6 minor points
- Minor pointExplore-OSA: evening lorundrostat 50 mg reduced morning systolic pressure 11.1 mmHg at Week 4 versus 1.0 mmHg with placebo.
- Minor pointExplore-OSA reported no evidence of serious safety events, including high blood potassium.
- Minor pointCommercial preparations advanced with an expanded medical affairs team and sales force in place.
- Minor pointThird-quarter research and development expenses fell to $22.668 million from $31.450 million a year earlier.
- Minor pointThird-quarter interest and other income rose to $5.947 million from $4.199 million a year earlier.
- Minor pointNine-month interest and other income rose to $17.752 million from $9.907 million a year earlier.
Negative
- Moderate pointLorundrostat approval remains pending FDA review, with a December 22, 2026 target decision date.
- Moderate pointNine-month net loss widened to $337.738 million from $122.417 million a year earlier.
- Moderate pointNet senior secured term loan totaled $98.273 million at September 30, 2026, versus none at year-end 2025. 7% of market cap
- Minor pointExplore-OSA showed no measurable change in the apnea-hypopnea index, a measure of sleep apnea frequency.
- Minor pointThird-quarter net loss widened to $57.328 million from $36.932 million a year earlier.
11 minor points
- Minor pointThird-quarter basic and diluted loss per share widened to $0.64 from $0.52 a year earlier.
- Minor pointThird-quarter general and administrative expenses rose to $37.419 million from $9.681 million a year earlier.
- Minor pointThird-quarter interest expense reached $3.188 million, versus none a year earlier, following the June 2026 loan.
- Minor pointNine-month basic and diluted loss per share widened to $3.95 from $1.94 a year earlier.
- Minor pointNine-month research and development expenses rose to $268.410 million from $107.607 million a year earlier.
- Minor pointNine-month general and administrative expenses rose to $83.057 million from $24.717 million a year earlier.
- Minor pointNine-month interest expense reached $4.023 million, versus none a year earlier.
- Minor pointCash, equivalents and investments fell to $624.672 million at September 30, 2026, from $656.635 million at year-end 2025.
- Minor pointTotal liabilities rose to $126.348 million at September 30, 2026, from $15.113 million at year-end 2025.
- Minor pointTotal assets fell to $630.123 million at September 30, 2026, from $661.806 million at year-end 2025.
- Minor pointStockholders’ equity fell to $503.775 million at September 30, 2026, from $646.693 million at year-end 2025.
News Explained
At
Key Figures
- PDUFA target date
- December 22, 2026
- FDA review of lorundrostat NDA
- Reached systolic blood pressure target
- 46%
- Launch-HTN, lorundrostat 50 mg, Week 12; target <130 mmHg
- SBP reduction
- More than two-thirds achieved ≥10 mmHg
- Launch-HTN participants receiving lorundrostat
- Albuminuria reduction
- 52% versus placebo
- Participants with CKD
- Morning SBP reduction
- 11.1 mmHg versus 1.0 mmHg with placebo
- Explore-OSA, lorundrostat 50 mg, Week 4
- Cash, cash equivalents and investments
- $624.7 million
- As of September 30, 2026
- General and administrative expenses
- $37.4 million versus $9.7 million
- Third quarter 2026 versus third quarter 2025
- Net loss
- $57.3 million versus $36.9 million
- Third quarter 2026 versus third quarter 2025
Previous Earnings Reports
-
Reported Q3 net loss of $36.9 million, R&D of $31.5 million, and cash runway into 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pdufa regulatory
new drug application regulatory
sbp medical
ckd medical
hyperkalemia medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 –
– New analyses from the pivotal Launch-HTN trial showed
– Transform-HTN open-label extension trial data selected for late-breaking presentation at American Heart Association Scientific Sessions 2026 –
– Conference call today at 4:30 p.m. ET –
RADNOR, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.
“With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval,” said Jon Congleton, Chief Executive Officer of Mineralys. “We also continue to highlight the data from our clinical trials in meetings with physicians and through presentations at scientific congresses, including our recent updates at AHA-HTN and ASN Kidney Week, and our upcoming presentation at the AHA Scientific Sessions. We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.”
Recent Highlights and Upcoming Milestones
- Lorundrostat New Drug Application (NDA) — The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.
- New Launch-HTN and Explore-OSA Data at the American Heart Association Hypertension Scientific Sessions (AHA-HTN) and American Society of Nephrology (ASN) Kidney Week 2026
- A new analysis of the pivotal Phase 3 Launch-HTN trial showed that at Week 12,
46% of lorundrostat-treated participants (50 mg) achieved the AHA/ACC guideline-recommended office systolic blood pressure (SBP) target of <130 mmHg, with more than two-thirds achieving an SBP reduction of ≥10 mmHg. Participants had uncontrolled or treatment-resistant hypertension despite treatment with two to five antihypertensive therapies. - An additional new analysis from Launch-HTN demonstrated that lorundrostat achieved similar blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD. Lorundrostat also reduced albuminuria by
52% versus placebo, validating similar findings in a prior trial in participants with established CKD. - Final results from the Phase 2 Explore-OSA trial in overweight or obese adults with moderate-to-severe OSA and hypertension showed that lorundrostat 50 mg taken once daily in the evening reduced morning SBP by 11.1 mmHg at Week 4 (p<0.0001), compared with a 1.0 mmHg reduction with placebo (p=NS). No measurable change in apnea-hypopnea index was observed. Lorundrostat exhibited a favorable safety and tolerability profile, with no evidence of serious safety events, including hyperkalemia.
- A new analysis of the pivotal Phase 3 Launch-HTN trial showed that at Week 12,
- Transform-HTN Open-Label Extension Trial — New long-term efficacy and safety data from the ongoing Transform-HTN open-label extension trial will be featured in a late-breaking presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.
- Commercial Launch Readiness — The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place. The Company continues to engage with leading hypertension experts and payers. Brand marketing preparations are well underway, and the Company is finalizing a full-service patient support program designed to ease access for physicians, their office staff and patients.
Third Quarter 2026 Financial Highlights
Cash, cash equivalents and investments were
Research and development (R&D) expenses for the quarter ended September 30, 2026, were
General and administrative (G&A) expenses were
Total other income, net was
Net loss was
Conference Call
The Company’s management team will host a conference call at 4:30 p.m. ET today, November 4, 2026. To access the call, please dial 1-877-704-4453 in the United States or 1-201-389-0920 outside the United States, referencing conference ID 13762560. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investors section of the Mineralys website here.
About Lorundrostat
Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40
Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.
Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding: the anticipated timing of the FDA’s review of Mineralys’ accepted NDA; the potential therapeutic benefits of lorundrostat; Mineralys’ expectations regarding activities to prepare for the commercial launch of lorundrostat; and the sufficiency of Mineralys’ cash, cash equivalents and investments to fund its operations. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the FDA’s review of Mineralys’ accepted NDA, including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com
Mineralys Therapeutics, Inc.
Condensed Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 22,668 | $ | 31,450 | $ | 268,410 | $ | 107,607 | |||||||
| General and administrative | 37,419 | 9,681 | 83,057 | 24,717 | |||||||||||
| Total operating expenses | 60,087 | 41,131 | 351,467 | 132,324 | |||||||||||
| Loss from operations | (60,087 | ) | (41,131 | ) | (351,467 | ) | (132,324 | ) | |||||||
| Other income (expense), net: | |||||||||||||||
| Interest and other income | 5,947 | 4,199 | 17,752 | 9,907 | |||||||||||
| Interest expense | (3,188 | ) | — | (4,023 | ) | — | |||||||||
| Total other income, net | 2,759 | 4,199 | 13,729 | 9,907 | |||||||||||
| Net loss | $ | (57,328 | ) | $ | (36,932 | ) | $ | (337,738 | ) | $ | (122,417 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.64 | ) | $ | (0.52 | ) | $ | (3.95 | ) | $ | (1.94 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 88,986,795 | 70,594,504 | 85,538,811 | 63,133,634 | |||||||||||
Mineralys Therapeutics, Inc.
Selected Financial Information
Condensed Balance Sheet Data
(in thousands)
(unaudited)
| September 30, | December 31, | ||||
| 2026 | 2025 | ||||
| Cash, cash equivalents and investments | $ | 624,672 | $ | 656,635 | |
| Total assets | $ | 630,123 | $ | 661,806 | |
| Senior secured term loan, net | $ | 98,273 | $ | — | |
| Total liabilities | $ | 126,348 | $ | 15,113 | |
| Total stockholders’ equity | $ | 503,775 | $ | 646,693 | |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is the FDA target decision date for Mineralys Therapeutics’ lorundrostat?
The FDA target decision date for lorundrostat is December 22, 2026. The application remains under review for treating hypertension in combination with other antihypertensive drugs.
What were Mineralys Therapeutics’ third-quarter 2026 loss and cash balance?
Mineralys reported a third-quarter net loss of $57.328 million and September 30 cash, cash equivalents and investments of $624.672 million. The comparable quarterly loss was $36.932 million, while cash, cash equivalents and investments totaled $656.635 million at December 31, 2025.
When will Mineralys present new long-term Transform-HTN results?
New long-term efficacy and safety data from the ongoing Transform-HTN open-label extension trial will feature in a late-breaking presentation at the American Heart Association Scientific Sessions 2026, taking place November 6–9 in Chicago.